Sarepta Therapeutics, Inc. SRPT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.18B— | $2.2B— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $45.14M+15.9% | $44.52M+18.0% | $49.72M+28.7% | $41.08M+3.3% | $38.96M+24.8% | ||
| —— | —— | —— | —— | -$248.39M-764% | ||
| —— | —— | —— | —— | —— | ||
| $25.15M-14.7% | $25.51M-10.7% | $26.07M+25.7% | $29.47M+122% | $29.5M— | ||
| $38.53M+71.1% | $37.63M+66.6% | $32.22M+88.1% | $34.69M+103% | $22.51M+45.7% | ||
| -$267.05M-195% | -$206.25M-202% | -$38.79M-134% | $167.3M+35.8% | $280.57M+81.0% | ||
| $211.97M-58.6% | $319.57M-19.1% | $481.23M+46.9% | $468.75M+65.2% | $512.02M+146% | ||
| —— | —— | —— | —— | —— | ||
| $31.14M+96.4% | $14.91M-5.9% | $14.65M-8.2% | $15.06M-6.4% | $15.86M-1.4% | ||
| -$180.57M-257% | -$168.34M-235% | -$80.15M-203% | $51.4M-35.3% | $115.14M+154% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$5.33M— | -$8.31M— | —— | —— | —— | ||
| —— | —— | —— | —— | $927.8M-49.4% | ||
| $6.64M— | $7.88M— | —— | —— | —— | ||
| $60.4M-59.2% | $101.97M-25.5% | $136.46M+15.7% | $150.79M+36.7% | $148.16M+49.6% | ||
| $294M-81.2% | $295.87M-85.2% | $1.16B-25.8% | $1.37B-21.3% | $1.57B-17.5% | ||
| $111.37M-39.8% | $123.4M-33.0% | $143.06M-20.7% | $171.58M-7.3% | $185.04M+1.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Sarepta Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.